HIV advances will fail to reduce global burden for now
Subject The implications of advances on HIV therapies. Significance A first-stage clinical trial on treating HIV and AIDS published its results in April. It showed that the use of a therapeutic antibody -- 3BNC117 -- against HIV/AIDS may be effective, safe and well-tolerated in humans. This demonstrates the potential of neutralising antibodies against HIV/AIDS and proves for the first time the feasibility of an antibody-based HIV/AIDS therapy. Impacts The less frequent dosage schedule of 3BNC117 might increase treatment compliance, reducing overall HIV transmission. The successful design of protective antibodies may have the capacity to confer protection against HIV in healthy individuals for life. This would effectively create an HIV vaccine, transforming HIV care worldwide.